LACTOLOGY FOUNDATION

Lactulose (ATC A06AD11) is an osmotic laxative considered compatible with breastfeeding, with minimal systemic absorption and negligible transfer into human milk, making adverse effects in breastfed infants unlikely. Available data and pharmacokinetic properties support its use in lactating women when clinically indicated, with standard precautions related mainly to maternal gastrointestinal and electrolyte effects.medpedia.framar+6

Pharmacological class and mechanism

Lactulose is a synthetic disaccharide derived from lactose, composed of one galactose and one fructose molecule, classified under ATC A06AD11 as an osmotically acting laxative. It is poorly absorbed in the small intestine (under about 3% of the oral dose), so most reaches the colon unchanged.ncbi.nlm.nih+6

In the colon, saccharolytic bacteria metabolize lactulose to organic acids (mainly lactic acid, with smaller amounts of acetic and formic acid), which lower intraluminal pH and increase osmotic water retention in the stool. The resulting softer, bulkier stools and stimulation of colonic motility underlie the laxative effect, usually evident within 24–48 hours of therapy initiation.farmacotherapeutischkompas+2

Lowering colonic pH also contributes to management of hepatic encephalopathy by trapping ammonia as non-absorbable ammonium ions and enhancing its fecal elimination. The acidic environment further suppresses urease‑producing bacteria while promoting bacteria that utilize ammonia for protein synthesis.hpra+2

Indications in the general population

Drugs in ATC class A06AD11 (lactulose preparations) are indicated primarily for:

• Chronic constipation in adults, including geriatric patients, when dietary and lifestyle measures are insufficient.duphalac+2
• Situations where soft stool is desired, such as in patients with hemorrhoids or after colorectal or anal surgery.hpra+2
• Prevention and treatment of hepatic encephalopathy, including portal-systemic encephalopathy and hepatic coma, usually as an adjunct to protein restriction and other supportive measures.wikipedia+2

Lactulose is widely available as a generic medicinal product and under various brand names (e.g. Duphalac and similar syrups), and is listed among essential medicines for constipation and hepatic encephalopathy in many formularies.lakemedelsverket+3

Dosage and administration

Lactulose is typically administered orally as a syrup or solution; rectal administration (retention enema) is reserved for acute hepatic encephalopathy when oral intake is not possible.medpedia.framar+2

• Adults: common initial oral doses for constipation range from 15–45 ml per day, in one or two divided doses, titrated to produce two to three soft stools daily. For hepatic encephalopathy, doses of 30–50 ml three times daily are frequently used, adjusted based on stool frequency and clinical response.farmacotherapeutischkompas+3
• Pediatric patients: dosing is weight- and age‑dependent, typically starting at 2.5–10 ml/day in infants and higher daily volumes in older children and adolescents, again titrated to achieve two to three soft stools daily.duphalac+3

Because the laxative effect may be delayed, dose adjustments are usually made every one to two days, with careful monitoring for diarrhea and electrolyte disturbances.medpedia.framar+2

Safety in lactation

Pharmacokinetics relevant to breastfeeding

Oral lactulose exhibits minimal systemic bioavailability, with less than approximately 3% of the administered dose absorbed from the gastrointestinal tract into the maternal circulation. Any absorbed fraction is rapidly eliminated via renal excretion within about 24 hours, whereas the bulk of the dose is metabolized in the colon and excreted in feces.doctronic+3

Given its poor systemic absorption, transfer of lactulose into breast milk is expected to be negligible; available pharmacokinetic and clinical data support very low or undetectable milk levels. LactMed and other lactation references consider lactulose unlikely to adversely affect breastfed infants, and some experts regard it as a laxative of choice during breastfeeding.sps+3

Clinical experience and recommendations

Clinical experience and guideline statements indicate that lactulose can be used during lactation without special precautions when treatment of maternal constipation or hepatic encephalopathy is required. Osmotic laxatives, including lactulose, are generally favored over stimulant agents in breastfeeding women because their passage into milk is low and they act mainly intraluminally.breastfeedingnetwork+2

Manufacturers and drug information sources describe adverse effects in nursing infants as unlikely, given the pharmacology and pharmacokinetics of lactulose, although they often recommend general caution as a standard labeling approach in the absence of controlled infant exposure data. No specific reports of clinically significant toxicity in breastfed infants attributable to maternal lactulose therapy have been documented in the major lactation databases.nhs+3

Lactation-specific risk assessment

Based on current evidence and its pharmacologic profile, lactulose in standard therapeutic doses is considered compatible with breastfeeding for term, healthy infants. Potential theoretical effects on the infant’s bowel function are minimal, as any lactulose that might reach milk would be in very low concentrations and rapidly eliminated by the infant.ncbi.nlm.nih+3

For lactation‑toxicology monographs, the infant risk can be characterized as negligible at typical maternal doses, with routine clinical monitoring of the mother’s gastrointestinal tolerance and hydration status rather than specific infant surveillance.doctronic+3

Maternal adverse effects and toxicity considerations

Maternal adverse reactions to lactulose are dose‑related and primarily gastrointestinal.cbg-meb+2

Common or very frequent reactions include:

• Flatulence, borborygmi and abdominal bloating, usually transient and diminishing after several days of treatment.cbg-meb+2
• Soft stools and dose‑dependent diarrhea, which is both the therapeutic endpoint and the principal limiting adverse effect.hpra+2

Less common reactions include nausea and vomiting, and, in susceptible patients (elderly, those with impaired renal function or high doses), dehydration and electrolyte disturbances such as hyponatremia, hypokalemia and reduced magnesium levels. Prolonged high‑dose use beyond six months warrants periodic monitoring of serum electrolytes (sodium, potassium, chloride, bicarbonate).farmacotherapeutischkompas+2

Lactulose is non‑nutritive and non‑digestible, so it does not contribute to weight gain; however, like other sugars it has a potential to promote dental caries in predisposed individuals.medpedia.framar

Toxicity data from animal studies show no evidence of systemic toxicity at high oral doses, and human data suggest a wide safety margin, although severe dehydration can precipitate lithium toxicity in psychiatric patients treated concomitantly with lithium salts. Allergic reactions are rare and mainly associated with underlying milk allergy or hypersensitivity to excipients.cbg-meb+1

Contraindications, cautions and interactions

Lactulose preparations in ATC A06AD11 are contraindicated or require caution in several clinical situations.hpra+2

Major contraindications:

• Galactosemia or strict galactose-free diets, due to the galactose content in lactulose formulations.medpedia.framar+1
• Known hypersensitivity to lactulose or product excipients.hpra+1
• Documented gastrointestinal obstruction or conditions requiring avoidance of increased intraluminal pressure.cbg-meb+1

Cautions:

• Diabetes mellitus, where even small systemic absorption of sugar and formulation excipients may influence glycemic control, particularly at higher doses.drugs+2
• Elderly or frail patients, in whom alternative osmotic laxatives such as sorbitol may produce fewer adverse effects like nausea.medpedia.framar
• Infants, especially in high doses or prolonged use, due to risk of hyponatremia and dehydration.hpra+1
• Pregnancy, where prolonged or excessive dosing could theoretically lead to electrolyte imbalance, although animal reproduction studies have not demonstrated teratogenicity and human data do not suggest fetal harm.drugs+2

Drug interactions:

• Non‑absorbable antacids co‑administered with lactulose may blunt its acidifying effect on colonic contents, potentially reducing efficacy in hepatic encephalopathy.medpedia.framar
• Concomitant oral anti‑infective therapy (e.g. neomycin) may alter colonic bacterial flora and interfere with lactulose metabolism and pH reduction; close clinical monitoring is advised.cbg-meb+1
• Combined use with other laxatives during hepatic encephalopathy treatment can mask under‑dosing of lactulose by causing loose stools from other mechanisms.hpra+1
• Co‑administration with diuretics, corticosteroids or amphotericin may enhance potassium loss and increase the risk of hypokalemia.medpedia.framar+1
• Lactulose-induced lowering of colonic pH can theoretically affect the release profiles of pH‑dependent enteric formulations, potentially altering drug bioavailability.medpedia.framar

Summary for lactation-toxicology classification

For the purposes of a lactation‑toxicology monograph, lactulose (A06AD11) can be summarized as follows:sps+3

• Pharmacologic group: non‑absorbed synthetic disaccharide osmotic laxative, with additional ammonia‑lowering effects in hepatic encephalopathy.atcddd.fhi+2
• Maternal indication: chronic constipation, situations requiring soft stools, hepatic encephalopathy.farmacotherapeutischkompas+2
• Lactation risk: negligible; minimal systemic absorption and very low anticipated milk transfer; regarded as compatible with breastfeeding and often preferred among laxatives.nhs+3
• Infant effects: no documented clinically significant adverse reactions; theoretical gastrointestinal effects are unlikely at expected exposure levels.ncbi.nlm.nih+1
• Monitoring: focus on maternal GI tolerance, hydration and electrolytes at higher or prolonged doses, especially in vulnerable populations.farmacotherapeutischkompas+2